These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
68. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Keskinbora K; Aydinli I Clin Neurol Neurosurg; 2008 Dec; 110(10):979-84. PubMed ID: 18620801 [TBL] [Abstract][Full Text] [Related]
69. Drugs for the acute treatment of migraine in children and adolescents. Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010 [TBL] [Abstract][Full Text] [Related]
70. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692 [TBL] [Abstract][Full Text] [Related]
71. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Corasaniti MT; Bagetta G; Nicotera P; Tarsitano A; Tonin P; Sandrini G; Lawrence GW; Scuteri D Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235366 [TBL] [Abstract][Full Text] [Related]
73. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Bayer O; Adrion C; Al Tawil A; Mansmann U; Strupp M; Trials; 2019 Dec; 20(1):813. PubMed ID: 31888723 [TBL] [Abstract][Full Text] [Related]
74. Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. Forbes RB; McCarron M; Cardwell CR Headache; 2020 Sep; 60(8):1542-1557. PubMed ID: 32668023 [TBL] [Abstract][Full Text] [Related]
75. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine. Ashina M; Cohen JM; Gandhi SK; Du E Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380 [TBL] [Abstract][Full Text] [Related]